Invention Grant
US08067529B2 Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
失效
来自人肿瘤抗原的免疫原性T辅助表位和使用所述表位的免疫治疗方法
- Patent Title: Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
- Patent Title (中): 来自人肿瘤抗原的免疫原性T辅助表位和使用所述表位的免疫治疗方法
-
Application No.: US11664627Application Date: 2005-09-09
-
Publication No.: US08067529B2Publication Date: 2011-11-29
- Inventor: Hans-Georg Rammensee , Toni Weinschenk , Jörn Dengjel
- Applicant: Hans-Georg Rammensee , Toni Weinschenk , Jörn Dengjel
- Applicant Address: DE Tubingen
- Assignee: Immatics Biotechnologies GmbH
- Current Assignee: Immatics Biotechnologies GmbH
- Current Assignee Address: DE Tubingen
- Agency: Baker Donelson Bearman Caldwell & Berkowitz, PC
- Priority: EP04023546 20041002
- International Application: PCT/EP2005/009719 WO 20050909
- International Announcement: WO2006/037421 WO 20060413
- Main IPC: C07H21/04
- IPC: C07H21/04 ; C07K5/00 ; C12N15/00
Abstract:
The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular renal cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 338 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.
Public/Granted literature
Information query
